Semaglutide is a drug often sold under brand names such as Wegovy and Ozempic
SHARE:
A drug called Semaglutide could reduce the risk of heart failure and strokes in obese people even if they don’t lose much weight, according to a new study.
The five-year study, led by Professor John Deanfield of University College London (UCL), analysed the effects of Semaglutide sold under brand names Wegovy and Ozempic.
It found that participants taking the medication had a 20% lower risk of heart attacks, stroke or death due to cardiovascular disease, regardless of weight lost.
After 20 weeks of being on the drug, 62% of patients had lost more than 5% of their bodyweight compared with 10% in the placebo group.
“Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat”, he added.
However, there isn’t yet evidence that the treatment can prevent major cardiovascular events.
Submitted Article
Headline
Short Headline
Standfirst
Published Article
HeadlineAnti-obesity drugs like Ozempic could reduce risk of heart attacks in obese patients, study says
Short HeadlineOzempic could reduce risk of health issues in obese patients
StandfirstThe results of the study suggest that the treatment could have effects beyond reducing unhealthy body fat.
A drug called Semaglutide could reduce the risk of heart failure and strokes in obese people even if they don’t lose much weight, according to a new study.
The five-year study, led by Professor John Deanfield of University College London (UCL), analysed the effects of Semaglutide sold under brand names Wegovy and Ozempic.
It found that participants taking the medication had a 20% lower risk of heart attacks, stroke or death due to cardiovascular disease, regardless of weight lost.
After 20 weeks of being on the drug, 62% of patients had lost more than 5% of their bodyweight compared with 10% in the placebo group.
“Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat”, he added.
However, there isn’t yet evidence that the treatment can prevent major cardiovascular events.
The first direct negotiations between Russian and Ukrainian officials since the breakdown of talks in 2022 have begun in Istanbul, as both sides revisit unresolved demands amid continued fighting on the ground
A devastating fire at Bicester Motion, a historic motoring and aviation centre located on a former RAF base in Oxfordshire, has claimed the lives of two firefighters and a member of the public.
